Jenna Philpott

6 days ago | pharmaceutical-technology.com | Jenna Philpott

The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships. Eli Lilly will use BigHat’s AI-driven Milliner platform. Credit: Just_Super via Getty Images. Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial intelligence (AI)-driven drug development.

1 week ago | pharmaceutical-technology.com | Jenna Philpott

Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder Ayrmid failed to deliver a binding offer or secure financing by the extended deadline. The announcement marks the second time Ayrmid has initiated discussions with bluebird without producing a fully financed proposal.

1 week ago | clinicaltrialsarena.com | Jenna Philpott

Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical trial for an ultra-rare disorder. GLM101 is being developed as a treatment for phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG), a rare and life-threatening genetic disorder with no approved treatments. Glycomine is currently conducting an open-label Phase II clinical trial (NCT06657859) at sites in Europe and the US, with 20 patients enrolled to date.

1 week ago | pharmaceutical-technology.com | Jenna Philpott

Skip to site menuSkip to page content Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical trial for an ultra-rare disorder. GLM101 is being developed as a treatment for phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG), a rare and life-threatening genetic disorder with no approved treatments.

1 week ago | clinicaltrialsarena.com | Jenna Philpott |Abigail Beaney |Manasi Vaidya

The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans for import tariffs. While President Trump has made several announcements on tariffs since he took office, things accelerated on 2 April, which was christened as ‘Liberation day’ when the administration announced reciprocal tariffs for a number of countries.